Abstract: Aromatase inhibitors (AI) are the leading care for the adjuvant treatment of hormone responsive carcinoma of the breast as  demonstrated in a number of large international phase III randomised trials. Aromatase inhibitorassociated arthralgia（AIA）was a somewhat unexpected side effect of this class of agents and has proven to be potentially problematic in clinical practice. The pathogenesis of AIA is not very clear currently, with the cause of most research focusing on estrogen deprivation，immune abnormalities，tenosynovial changes and joint effusions. It is extremely urgent that we evaluate this syndrome and select appropriate therapeutic strategies to reduce the incidence of AIA，thereby improving breast cancerrelated outcomes.

Key words: Pain, Breast neoplasms, Aromatase inhibitors